Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…Levodopa and dopamine agonists dosage changes after Opicapone introduction
Objective: We aim to analyze changes in levodopa and dopamine agonists (DA) dosage after introduction of opicapone (OPC) in a daily clinical practice setting. Background:…Motor subtype change between OFF and ON periods in patients with Parkinson’s disease
Objective: To identify if there is any difference in the motor subtype of PwPD between "off" stage and "on" stage. Background: Patients with Parkinson’s disease…Efficacy and tolerability of opicapone in Parkinson´s disease in usual clinical practice
Objective: To evaluate the efficacy and tolerability of opicapone in usual clinical practice in patients with Parkinson's disease (PD). Background: Opicapone is a recently approved…Opicapone management: A 2-year follow up real- life practice study
Objective: The aim of this work is to show our clinical experience with opicapone in real practice in a cohort of 68 parkinsonian patients followed…Management of parkinsonian patients with long-term DBS and incomplete control of symptoms
Objective: We want to evaluate if apomorphine infusions can improve symptom control in PD patients with long standing DBS and functional decline. Background: Deep brain stimulation…Efficacy and Safety of High Doses of Safinamide in Advanced Parkinson’s Disease Patients in a Real-World Experience
Objective: To evaluate in a real-world experience high doses of safinamide in patients with fluctuating Parkinson's disease (PD). Background: Standard doses of safinamide (50-100 mg)…Dyskinesia and bradykinesia severity patterns in Parkinson’s disease using a wearable sensor
Objective: To determine if dyskinesia and bradykinesia severity has a diurnal pattern in Parkinson’s disease (PD) using wearable sensor data. Background: Diurnal fluctuations in PD…A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson’s disease patients
Objective: Here we investigated the consequences of the shift from rasagiline (RS) to SF in fluctuating PD patients. To this end, we selected patients from…Freezing of gait that persists from the OFF to the ON state is associated with memory impairments in Parkinson’s disease
Objective: To examine cognitive correlates associated with FOG that persists in both the ON and OFF medication states (ONOFF-FOG) vs. FOG that appears only in…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 24
- Next Page »